Related references
Note: Only part of the references are listed.Benefits of treatment with rasagiline for fatigue symptoms in patients with early Parkinson's disease
F. Stocchi
EUROPEAN JOURNAL OF NEUROLOGY (2014)
Cardiac safety of rasagiline, a selective monoamine oxidase type B inhibitor for the treatment of Parkinson's disease: a thorough QT/QTc study
Boaz Mendzelevski et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2014)
Pharmacological Treatment of Parkinson Disease A Review
Barbara S. Connolly et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Chronic monoamine oxidase-B inhibitor treatment blocks monoamine oxidase-A enzyme activity
Jasmin Bartl et al.
JOURNAL OF NEURAL TRANSMISSION (2014)
Randomized, Controlled Trial of Rasagiline as an Add-on to Dopamine Agonists in Parkinson's Disease
Robert A. Hauser et al.
MOVEMENT DISORDERS (2014)
Evaluation of the safety and tolerability of rasagiline in the treatment of the early stages of Parkinson's disease
Francois Viallet et al.
CURRENT MEDICAL RESEARCH AND OPINION (2013)
Rasagiline meta-analysis: a spotlight on clinical safety and adverse events when treating Parkinson's disease
Julian Solis-Garcia del Pozo et al.
EXPERT OPINION ON DRUG SAFETY (2013)
Revelation in the neuroprotective functions of rasagiline and selegiline: the induction of distinct genes by different mechanisms
Makoto Naoi et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2013)
Efficacy and safety of rasagiline as an adjunct to levodopa treatment in Chinese patients with Parkinson's disease: a randomized, double-blind, parallel-controlled, multi-centre trial
Lina Zhang et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2013)
''70th Birthday Professor Riederer'' Induction of glial cell line-derived and brain-derived neurotrophic factors by rasagiline and (-)deprenyl: a way to a disease-modifying therapy?
Wakako Maruyama et al.
JOURNAL OF NEURAL TRANSMISSION (2013)
Rapid onset of efficacy of rasagiline in early Parkinson's disease
Sandro Zambito Marsala et al.
NEUROLOGICAL SCIENCES (2013)
Rasagiline A Review of its Use in the Treatment of Idiopathic Parkinson's Disease
Sheridan M. Hoy et al.
DRUGS (2012)
Indirect Comparisons of Adverse Events and Dropout Rates in Early Parkinson's Disease Trials of Pramipexole, Ropinirole, and Rasagiline
Francisco J. Zagmutt et al.
INTERNATIONAL JOURNAL OF NEUROSCIENCE (2012)
The Monoamine Oxidase Type B Inhibitor Rasagiline in the Treatment of Parkinson Disease: Is Tyramine a Challenge?
Jack J. Chen et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2012)
A critical review of evidence for preclinical differences between rasagiline and selegiline
Manfred Gerlach et al.
BASAL GANGLIA (2012)
Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson's disease
F. Stocchi et al.
EUROPEAN JOURNAL OF NEUROLOGY (2011)
Safety of rasagiline for the treatment of Parkinson's disease
Santiago Perez-Lloret et al.
EXPERT OPINION ON DRUG SAFETY (2011)
Rasagiline Time to Onset of Antiparkinson Effect is Similar When Used as a Monotherapy or Adjunct Treatment
Ronald E. Wilson et al.
NEUROLOGIST (2011)
Efficacy and tolerability of rasagiline in daily clinical use - a post-marketing observational study in patients with Parkinson's disease
H. Reichmann et al.
EUROPEAN JOURNAL OF NEUROLOGY (2010)
Clinical Pharmacology Tyramine Challenge Study to Determine the Selectivity of the Monoamine Oxidase Type B (MAO-B) Inhibitor Rasagiline
Tamar Goren et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2010)
The neuroprotective mechanism of 1-(R)-aminoindan, the major metabolite of the anti-parkinsonian drug rasagiline
Orit Bar-Am et al.
JOURNAL OF NEUROCHEMISTRY (2010)
Cost Effectiveness of Rasagiline and Pramipexole as Treatment Strategies in Early Parkinson's Disease in the UK Setting An Economic Markov Model Evaluation
Alan Haycox et al.
DRUGS & AGING (2009)
Long-term Outcome of Early Versus Delayed Rasagiline Treatment in Early Parkinson's Disease
Robert A. Hauser et al.
MOVEMENT DISORDERS (2009)
A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease
C. Warren Olanow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Transtelephonic home blood pressure to assess the monoamine oxidase-B inhibitor rasagiline in Parkinson disease
William B. White et al.
HYPERTENSION (2008)
Rasagiline - A review of its use in the management of Parkinson's disease
Vicki Oldfield et al.
DRUGS (2007)
Rasagiline: A second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease
Jack J. Chen et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2006)
Safety of rasagiline in elderly patients with Parkinson disease
CG Goetz et al.
NEUROLOGY (2006)
Rasagiline improves quality of life in patients with early Parkinson's disease
KM Biglan et al.
MOVEMENT DISORDERS (2006)
Cost-utility model of rasagiline in the treatment of advanced Parkinson's disease in Finland
J Hudry et al.
ANNALS OF PHARMACOTHERAPY (2006)
Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline
J. Antonelle deMarcaida et al.
MOVEMENT DISORDERS (2006)
Clinical pharmacology of rasagiline: A novel, second-generation propargylamine for the treatment of Parkinson disease
JJ Chen et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial
O Rascol et al.
LANCET (2005)
Long term motor complications of levodopa: clinical features, mechanisms, and management strategies
BR Thanvi et al.
POSTGRADUATE MEDICAL JOURNAL (2004)
Perspectives on MAO-B in aging and neurological disease - Where do we go from here?
MJ Kumar et al.
MOLECULAR NEUROBIOLOGY (2004)
Tolerability, safety, pharmacodynamics, and pharmacokinetics of rasagiline:: A potent, selective, and irreversible monoamine oxidase type B inhibitor
JJ Thébault et al.
PHARMACOTHERAPY (2004)
Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: A double-blind study as adjunctive therapy to levodopa
JM Rabey et al.
CLINICAL NEUROPHARMACOLOGY (2000)
Share Paper
